50 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
, train, and retain adequate numbers of effective sales, technical support, and marketing personnel;
the inability of sales personnel to obtain access … our competitors access to the same technologies licensed to us.
Moreover, some of our owned and in-licensed patents or patent applications or future
POS AM
700o13yfa3bgl3ine
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-10.1
ccpc8bvbq2byfzl0kb
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
gm62e0qobdg82 41uya
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
ijgzx0gj2mcjhwzqchmv
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
5u73mnt
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
8xuczzos5urukhy84403
16 Nov 23
Shelf registration
5:23pm
8-K
EX-10.1
lqlsiii46p 2w7m
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.6
klcn39r1z2 zejfj8
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm